## Supplemental data

## Supplemental methods

Mononuclear cells were stained with fluorescent antibodies, acquired on a BD FACScan flow cytometer, and analyzed using FlowJo software. All cells were stained with CD3 PerCP (BD 347304; clone SK7) and CD56 APC (BD 341025; clone NCAM16.2). To identify the mature NK cells, FITC conjugated anti-KIR antibodies CD158a (BD 556062; clone HP3E4), CD158b (BD 559784; clone CH-L) and NKB1 (BD 555966; clone DX9) and PE conjugated antibody NKG2A (Beckman Coulter IM3291; clone Z199) were also added. Lymphocytes were identified by light scatter and NK cells were identified as CD56+CD3. The NK cells were further gated into KIR+NKG2A+, KIR+NKG2A-, KIR-NKG2A+ and KIR-NKG2A- quadrants. To identify T cell subsets, cells were stained with CD3 PerCP and CD56 APC, as above, along with CD4 FITC (BD 340133; clone SK3) and CD8 PE (BD 340046; clone SK1). T cells were identified as CD3-CD56+ lymphocytes and further gated into CD4+ and CD8+ subsets.

Table S1: Results of univariate regression

Table 31. Results of utilivaria					1		
	Regression						
Covariate	coefficient	SE	95%CI		P		
CD4 <sup>+</sup> T cells (% of lymphocytes)							
Graft source (reference: PB)							
BM	-9.18	1.72	-12.57	-5.79	<.0001		
CD8+ T cells (% of lymphocytes)							
Graft source (reference: PB)							
ВМ	0.76	2.63	-4.41	5.94	0.77		
NK cells total (% of lymphocytes)							
Graft source (reference: PB)							
BM	11.68	3.25	5.28	18.07	0.0004		
CD56 <sup>bright</sup> NK cells (% of NK cells) <sup>1</sup>							
Graft source (reference: PB)							
BM	8.58	2.44	3.78	13.38	0.0005		
KIR+NKG2A NK cells (% of NK cells)							
Graft source (reference: PB)							
BM	-0.67	1.96	-4.52	3.19	0.73		

<sup>1</sup>Because CD56<sup>bright</sup> NK cells (% of NK cells) and CD56<sup>dim</sup> NK cells (% of NK cells) add up to 100%, the regression models for the two are mathematically equivalent and only differ in the direction of the estimated regression coefficients of covariates. Therefore, only models for CD56<sup>bright</sup> NK cells are shown. BM: Bone marrow; CI: Confidence interval; NK: Natural killer; PB: Peripheral blood; SE: standard error

Table S2: Results of multivariable regressions with graft source, CMV group, and their interaction, unadjusted or adjusted for grade II-IV acute GVHD by day 100

their interaction, unadjusted or adj	Regression	<u> </u>		riib by	day 100		
Covariate	coefficient	SE	95%CI		P		
CD4 <sup>+</sup> T cells (% of lymphocytes)							
Graft source (reference: PB)							
BM	-6.65	2.54	-11.65	-1.65	0.01		
CMV group (reference: CMV-)	-0.05	2.07	-11.00	-1.00	0.09		
CMVr	-3.63	4.99	-13.46	6.19	0.09		
CMV+	-1.22	2.49	-6.12	3.67	0.47		
Graft source x CMV group	-1.22	2.49	-0.12	3.07	0.53		
BM x CMVr	-3.38	6.13	-15.47	8.70	0.53		
BM x CMV+	-4.02	3.64	-13.47	3.16	0.38		
Graft source (reference: PB)	ytes), adjuste	ea for g	rade II-IV	абупц	) 		
BM	-6.76	2.54	-11.76	-1.75	0.01		
CMV group (reference: CMV-)	-0.70	2.54	-11.70	-1.73	0.10		
CMVr	-3.86	5.00	-13.70	5.99	0.10		
CMV+	-1.11	2.49	-6.02	3.79	0.44		
Graft source x CMV group	-1.11	2.49	-0.02	3.19	0.54		
BM x CMVr	-3.07	6.15	-15.18	9.05	0.54		
BM x CMV+	-3.07	3.65	-11.16	3.21	0.02		
aGVHD grade II-IV (reference: No)	-3.91	3.03	-11.10	3.21	0.20		
Yes	1.41	1.73	-2.00	4.81	0.42		
				4.01	0.42		
	s (% of lymph	locytes	)	1	<u> </u>		
Graft source (reference: PB) BM	-7.23	3.61	-14.34	-0.11	0.05		
CMV group (reference: CMV-)	-1.23	3.01	-14.34	-0.11	<.0001		
CMVr	10.18	7.10	-3.81	24.16	0.15		
CMV+	8.17	3.54	1.21	15.14	0.13		
Graft source x CMV group	0.17	3.54	1.21	15.14	0.02		
BM x CMVr	12.61	8.73	-4.59	29.80	0.04		
	BM x CMV+ 12.55 5.18 2.33 22.76 0.02 CD8+ T cells (% of lymphocytes), adjusted for grade II-IV aGVHD						
	ytes), adjuste	ea for g	rade II-IV	aGVHL	) 		
Graft source (reference: PB) BM	-6.89	2 60	-13.98	0.19	0.06		
	-0.09	3.60	-13.90	0.19			
CMV group (reference: CMV-)	10.00	7.07	2.04	24.02	<.0001		
CMVr	10.89	7.07	-3.04	24.82	0.12		
CMV+ Graft source x CMV group	7.82	3.52	0.88	14.77	0.03		
BM x CMVr	11 50	0.70	5.56	20 72	0.05 0.18		
BM x CMV+	11.59 12.39	8.70 5.16	-5.56	28.73			
	12.38	5.16	2.23	22.56	0.02		
aGVHD grade II-IV (reference: No) Yes	-4.53	2.45	-9.35	0.29	0.07		
NK cells total (% of lymphocytes)							
Graft source (reference: PB)	16.01	4.70	7 04	25.04	0.0005		
BM	16.61	4.72	7.31	25.91	0.0005		

CMV group (reference: CMV-)	CMV group (reference: CMV)					0.000		
CMV+       -8.24       4.63       -17.35       0.87       0.08         Graft source x CMV group       -10.19       11.34       -32.54       12.16       0.37         BM x CMV+       -7.10       6.78       -20.46       6.25       0.30         NK cells total (% of lymphocytes), adjusted for grade II-IV aGVHD         Graft source (reference: PB) BM       15.97       4.66       6.78       25.16       0.000         CMV group (reference: CMV-)       -6.73       9.17       -24.79       11.34       0.46         CMV+       -7.57       4.57       -16.57       1.44       0.10         Graft source x CMV group       BM x CMV+       -8.04       11.22       -30.14       14.07       0.47         BM x CMV+       -8.04       11.22       -30.14       14.07       0.47         BM x CMV+       -8.68       3.17       2.44       14.92       0.01         CD56 <sup>bright</sup> NK cells (% of NK cells)*         CMVir group (reference: PB)         BM       11.86       3.56       4.84       18.87       0.00         CMVr       -2.96       7.00       -16.75       10.33       0.67         CMVr       -3.60		E 25	0.20	22.64	12.02			
Graft source x CMV group BM x CMVr BM x CMVr BM x CMV+         -10.19 -7.10         11.34 6.78         -32.54 -20.46         12.16 6.25         0.30 0.30           NK cells total (% of lymphocytes), adjusted for grade II-IV aGVHD           Graft source (reference: PB) BM         15.97         4.66         6.78         25.16         0.000           CMV group (reference: CMV-) CMVr CMV+         -6.73         9.17         -24.79         11.34         0.46           CMV+         -7.57         4.57         -16.57         1.44         0.10           Graft source x CMV group BM x CMVr BM x CMV+         -8.04         11.22         -30.14         14.07         0.47           BM x CMV+         -6.81         6.69         -19.99         6.37         0.31           Graft source (reference: PB) BM         11.86         3.56         4.84         18.87         0.001           CMV group (reference: CMV-) CMVr         -2.96         7.00         -16.75         10.83         0.67           CMV group (reference: CMV-) CMV+         -3.60         3.49         -10.48         3.27         0.30           BM x CMV+         -2.96         7.00         -16.75         10.83         0.67           CMV group (reference: CMV-) CMVr         -3.60         3.49								
BM x CMVr		-0.24	4.03	-17.33	0.67			
BM x CMV+		-10 19	11 34	-32 54	12 16			
NK cells total (% of lymphocytes), adjusted for grade II-IV aGVHD			_					
Straft source (reference: PB)								
BM	, , , ,	<u> </u>						
CMV group (reference: CMV-)	,	15.97	4.66	6.78	25.16	0.0007		
CMVr CMV+	CMV group (reference: CMV-)					0.003		
Graft source x CMV group   RM x CMVr   RM x CMVr   RM x CMV+   RM x CMV   RM x CMV+   RM x		-6.73	9.17	-24.79	11.34	0.46		
BM x CMVr	CMV+	-7.57	4.57	-16.57	1.44	0.10		
BM x CMV+   -6.81   6.69   -19.99   6.37   0.31     aGVHD grade II-IV (reference: No) Yes   8.68   3.17   2.44   14.92   0.01     CD56bright NK cells (% of NK cells)     Graft source (reference: PB) BM   11.86   3.56   4.84   18.87   0.001     CMV group (reference: CMV-)	Graft source x CMV group					0.54		
AGVHD grade II-IV (reference: No) Yes			11.22	-30.14				
Yes         8.68         3.17         2.44         14.92         0.01           CD56 <sup>bright</sup> NK cells (% of NK cells)¹           Graft source (reference: PB) BM         11.86         3.56         4.84         18.87         0.001           CMV group (reference: CMV-) CMVr         -2.96         7.00         -16.75         10.83         0.67           CMV+         -3.60         3.49         -10.48         3.27         0.30           Graft source x CMV group BM x CMVr         -13.29         8.56         -30.14         3.57         0.12           BM x CMV+         -2.06         5.11         -12.14         8.01         0.69           N CD56 <sup>bright</sup> NK cells (% of NK cells)¹, adjusted for grade II-IV aGVHD           Graft source (reference: PB) BM         11.80         3.57         4.76         18.83         0.001           CMV group (reference: CMV-) CMVr         -3.09         7.02         -16.93         10.75         0.66           CMV+         -3.54         3.50         -10.43         3.36         0.31           Graft source x CMV group BM x CMV+         -13.08         8.59         -30.01         3.85         0.13           BM x CMV+         -2.04         5.12         -12.13         8.06		-6.81	6.69	-19.99	6.37	0.31		
CD56bright NK cells (% of NK cells)	•							
Staft source (reference: PB)			1		14.92	0.01		
BM       11.86       3.56       4.84       18.87       0.001         CMV group (reference: CMV-)       -2.96       7.00       -16.75       10.83       0.67         CMV+       -3.60       3.49       -10.48       3.27       0.30         Graft source x CMV group       -13.29       8.56       -30.14       3.57       0.12         BM x CMV+       -2.06       5.11       -12.14       8.01       0.69         N CD56 <sup>bright</sup> NK cells (% of NK cells)¹, adjusted for grade II-IV aGVHD         Graft source (reference: PB)         BM       11.80       3.57       4.76       18.83       0.001         CMV group (reference: CMV-)       -3.09       7.02       -16.93       10.75       0.66         CMV+       -3.54       3.50       -10.43       3.36       0.31         Graft source x CMV group         BM x CMV+       -13.08       8.59       -30.01       3.85       0.13         BM x CMV+       -2.04       5.12       -12.13       8.06       0.69         Graft source (reference: No)       0.84       2.43       -3.94       5.61       0.73         CMV group (reference: PB)       -2.90 <td< td=""><td></td><td>cells (% of</td><td>NK cells</td><td>s)<sup>1</sup></td><td>I</td><td>Π</td></td<>		cells (% of	NK cells	s) <sup>1</sup>	I	Π		
CMV group (reference: CMV-)	,	44.00	0.50	4.04	40.07	0.004		
CMVr CMV+         -2.96 -3.60         7.00 3.49         -16.75 -10.48         10.83 3.27         0.30           Graft source x CMV group BM x CMVr BM x CMV+         -13.29 -2.06         8.56 5.11         -30.14 3.57         3.57         0.12 8.01         0.69           N CD56 <sup>bright</sup> NK cells (% of NK cells)¹, adjusted for grade II-IV aGVHD           Graft source (reference: PB) BM         11.80         3.57         4.76         18.83         0.001           CMV group (reference: CMV-) CMVr         -3.09 -3.54         7.02         -16.93         10.75         0.66           CMV+         -3.54         3.50         -10.43         3.36         0.31           Graft source x CMV group BM x CMV+         -13.08         8.59         -30.01         3.85         0.13           BM x CMV+         -2.04         5.12         -12.13         8.06         0.69           Graft source (reference: No) Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A* NK cells (% of NK cells)           CMV group (reference: CMV-) CMVr         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00  <		11.86	3.56	4.84	18.87			
CMV+       -3.60       3.49       -10.48       3.27       0.30         Graft source x CMV group BM x CMVr       -13.29       8.56       -30.14       3.57       0.12         BM x CMV+       -2.06       5.11       -12.14       8.01       0.69         N CD56 <sup>bright</sup> NK cells (% of NK cells)¹, adjusted for grade II-IV aGVHD         Graft source (reference: PB) BM       11.80       3.57       4.76       18.83       0.001         CMV group (reference: CMV-) CMVr       -3.09       7.02       -16.93       10.75       0.66         CMV+       -3.54       3.50       -10.43       3.36       0.31         Graft source x CMV group BM x CMV+       -13.08       8.59       -30.01       3.85       0.13         BM x CMV+       -2.04       5.12       -12.13       8.06       0.69         GRYHD grade II-IV (reference: No) Yes       0.84       2.43       -3.94       5.61       0.73         Graft source (reference: PB) BM       -2.90       2.72       -8.26       2.47       0.29         CMV group (reference: CMV-) CMVr       5.58       5.14       -4.55       15.70       0.28         CMV+       8.38       2.63       3.20	• • •	0.00	7.00	40.75	40.00			
Graft source x CMV group       -13.29       8.56       -30.14       3.57       0.12         BM x CMV+       -2.06       5.11       -12.14       8.01       0.69         N CD56 <sup>bright</sup> NK cells (% of NK cells)¹, adjusted for grade II-IV aGVHD         Graft source (reference: PB)         BM       11.80       3.57       4.76       18.83       0.001         CMV group (reference: CMV-)       -3.09       7.02       -16.93       10.75       0.66         CMV+       -3.54       3.50       -10.43       3.36       0.31         Graft source x CMV group       -13.08       8.59       -30.01       3.85       0.13         BM x CMV+       -2.04       5.12       -12.13       8.06       0.69         AGVHD grade II-IV (reference: No)       0.84       2.43       -3.94       5.61       0.73         KIR+NKG2A⁻ NK cells (% of NK cells)         Graft source (reference: PB)         BM       -2.90       2.72       -8.26       2.47       0.29         CMV group (reference: CMV-)       5.58       5.14       -4.55       15.70       0.28         CMV+       8.38       2.63       3.20       13.57 <t< td=""><td>_</td><td></td><td></td><td></td><td></td><td></td></t<>	_							
BM x CMVr		-3.60	3.49	-10.46	3.21			
BM x CMV+		40.00	0.50	20.44	0.57			
N CD56bright NK cells (% of NK cells)¹, adjusted for grade II-IV aGVHD								
Graft source (reference: PB)         11.80         3.57         4.76         18.83         0.001           CMV group (reference: CMV-)         -3.09         7.02         -16.93         10.75         0.66           CMV+         -3.54         3.50         -10.43         3.36         0.31           Graft source x CMV group         -13.08         8.59         -30.01         3.85         0.13           BM x CMV+         -2.04         5.12         -12.13         8.06         0.69           aGVHD grade II-IV (reference: No) Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A- NK cells (% of NK cells)           Graft source (reference: PB) BM         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-) CMVr         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00		I.	1					
BM       11.80       3.57       4.76       18.83       0.001         CMV group (reference: CMV-)       -3.09       7.02       -16.93       10.75       0.66         CMV+       -3.54       3.50       -10.43       3.36       0.31         Graft source x CMV group       -13.08       8.59       -30.01       3.85       0.13         BM x CMV+       -2.04       5.12       -12.13       8.06       0.69         aGVHD grade II-IV (reference: No) Yes       0.84       2.43       -3.94       5.61       0.73         KIR+NKG2A- NK cells (% of NK cells)         CMV group (reference: PB) BM       -2.90       2.72       -8.26       2.47       0.29         CMV group (reference: CMV-) CMV+       5.58       5.14       -4.55       15.70       0.28         CMV+       8.38       2.63       3.20       13.57       0.00		cens), adju	Stea for	grade II-	iv agv	п <del>и</del>		
CMV group (reference: CMV-)       -3.09       7.02       -16.93       10.75       0.66         CMV+       -3.54       3.50       -10.43       3.36       0.31         Graft source x CMV group       -13.08       8.59       -30.01       3.85       0.13         BM x CMV+       -2.04       5.12       -12.13       8.06       0.69         aGVHD grade II-IV (reference: No) Yes       0.84       2.43       -3.94       5.61       0.73         KIR+NKG2A- NK cells (% of NK cells)         Graft source (reference: PB) BM       -2.90       2.72       -8.26       2.47       0.29         CMV group (reference: CMV-) CMVr       5.58       5.14       -4.55       15.70       0.28         CMV+       8.38       2.63       3.20       13.57       0.00	,	11.80	3 57	4 76	18 83	0.001		
CMVr         -3.09         7.02         -16.93         10.75         0.66           CMV+         -3.54         3.50         -10.43         3.36         0.31           Graft source x CMV group         -13.08         8.59         -30.01         3.85         0.13           BM x CMV+         -2.04         5.12         -12.13         8.06         0.69           aGVHD grade II-IV (reference: No) Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A- NK cells (% of NK cells)           Graft source (reference: PB) BM         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-) CMVr         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00		11.00	0.07	1.70	10.00			
CMV+         -3.54         3.50         -10.43         3.36         0.31           Graft source x CMV group BM x CMVr BM x CMV+         -13.08 -2.04         8.59 5.12         -30.01 -12.13         3.85 0.13 8.06         0.13 0.69           aGVHD grade II-IV (reference: No) Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A- NK cells (% of NK cells)           Graft source (reference: PB) BM         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-) CMVr         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00		-3 09	7.02	-16 93	10.75			
Graft source x CMV group         -13.08         8.59         -30.01         3.85         0.13           BM x CMV+         -2.04         5.12         -12.13         8.06         0.69           aGVHD grade II-IV (reference: No) Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A- NK cells (% of NK cells)           Graft source (reference: PB) BM         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-) CMVr         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00								
BM x CMVr BM x CMV+       -13.08 -2.04       8.59 5.12       -30.01 -12.13       3.85 8.06       0.13 0.69         aGVHD grade II-IV (reference: No) Yes       0.84       2.43       -3.94       5.61       0.73         KIR+NKG2A- NK cells (% of NK cells)         Graft source (reference: PB) BM       -2.90       2.72       -8.26       2.47       0.29         CMV group (reference: CMV-) CMVr       5.58 8.38       5.14       -4.55 5.14       15.70 15.70       0.28 0.28         CMV+       8.38       2.63       3.20       13.57       0.00		0.0.	0.00		0.00			
BM x CMV+         -2.04         5.12         -12.13         8.06         0.69           aGVHD grade II-IV (reference: No) Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A* NK cells (% of NK cells)           Graft source (reference: PB) BM         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-) CMVr         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00		-13.08	8 59	-30.01	3 85			
aGVHD grade II-IV (reference: No) Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A- NK cells (% of NK cells)           Graft source (reference: PB) BM         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-) CMVr         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00								
Yes         0.84         2.43         -3.94         5.61         0.73           KIR+NKG2A- NK cells (% of NK cells)           Graft source (reference: PB)         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-)         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00								
Graft source (reference: PB)         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-)         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00	,	0.84	2.43	-3.94	5.61	0.73		
Graft source (reference: PB)         -2.90         2.72         -8.26         2.47         0.29           CMV group (reference: CMV-)         5.58         5.14         -4.55         15.70         0.28           CMV+         8.38         2.63         3.20         13.57         0.00								
BM     -2.90     2.72     -8.26     2.47     0.29       CMV group (reference: CMV-)     5.58     5.14     -4.55     15.70     0.28       CMV+     8.38     2.63     3.20     13.57     0.00		,						
CMVr       5.58       5.14       -4.55       15.70       0.28         CMV+       8.38       2.63       3.20       13.57       0.00	,	-2.90	2.72	-8.26	2.47	0.29		
CMVr       5.58       5.14       -4.55       15.70       0.28         CMV+       8.38       2.63       3.20       13.57       0.00	CMV group (reference: CMV-)					<.0001		
	CMVr	5.58	5.14	-4.55	15.70	0.28		
Graft source x CMV group 0.03	CMV+	8.38	2.63	3.20	13.57	0.00		
	Graft source x CMV group					0.03		
BM x CMVr 14.92 6.31 2.49 27.35 0.02		14.92	6.31	2.49	27.35	0.02		
BM x CMV+ -2.01 3.88 -9.65 5.64 0.61	BM x CMV+	-2.01	3.88	-9.65	5.64	0.61		
KIR+NKG2A- NK cells (% of NK cells), adjusted for grade II-IV aGVHD	KIR+NKG2A- NK cells (% of N	K cells), adju	sted for	grade II	-IV aGV	HD		

Graft source (reference: PB)					
BM	-2.37	2.71	-7.72	2.97	0.38
CMV group (reference: CMV-)					0.04
CMVr	6.20	5.11	-3.87	16.26	0.23
CMV+	7.95	2.62	2.79	13.12	0.003
Graft source x CMV group					0.04
BM x CMVr	13.72	6.28	1.34	26.11	0.03
BM x CMV+	-2.30	3.85	-9.89	5.29	0.55
aGVHD grade II-IV (reference: No)					
Yes	-3.86	1.83	-7.47	-0.26	0.04

<sup>1</sup>Because CD56<sup>bright</sup> NK cells (% of NK cells) and CD56<sup>dim</sup> NK cells (% of NK cells) add up to 100%, the regression models for the two are mathematically equivalent and only differ in the direction of the estimated regression coefficients of covariates. Therefore, only models for CD56<sup>bright</sup> NK cells are shown. aGVHD: acute graft-versus-host disease; BM: Bone marrow; CI: Confidence interval; CMV: Cytomegalovirus; CMVr, patients who reactivated CMV by day 100; CMV+, CMV-seropositive patients who did not reactivate CMV by day 100; CMV-, CMV-seronegative patients who did not reactivate CMV; NK: Natural killer; PB: Peripheral blood; SE: standard error




Figure S1: Association of CMV reactivation with T- and NK-cell reconstitution at 100 days in unrelated donor allografts using bone marrow vs. peripheral blood as a graft source. The absolute counts of (A) CD4+ T cells, (B) CD8+ T cells, and (C) total NK cells were determined based on a lymphocyte gate determined by forward and side scatter. The NK cells (CD56+/CD56- gate) were subsetted into (D) CD56bright, (E) CD56dim, and (F) KIR+NKG2A- NK cells in three groups based on CMV reactivation status and in bone marrow vs. peripheral blood groups, separately. Red numbers on the X-axis show medians. CMVr, patients who reactivated CMV by day 100; CMV+, CMV-seropositive patients who did not reactivate CMV by day 100; and CMV-, CMV-seronegative patients who did not reactivate CMV by day 100